Back to Search
DR. JENNIFER EKDAHL CORTES M.D.
M.D.
Internal Medicine Physician
NPI: 1225204381Individual
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
43369(AZ)
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
43369(AZ)
Research & Publications (20)
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
PMID 19508387·J Cell Mol Med·2010
7-preclinical
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.
PMID 19369233·Blood·2009
8-other
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
PMID 19224852·J Clin Oncol·2009
8-other
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
PMID 19332983·Acta Haematol·2009
6-review
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
PMID 19369231·Blood·2009
3-trial
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
PMID 19090005·Cancer·2009
8-other
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
PMID 19181650·Mayo Clin Proc·2009
6-review
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.
PMID 19193436·Leuk Res·2009
3-trial
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
PMID 19280591·Cancer·2009
3-trial
T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1.
PMID 19294558·Leuk Lymphoma·2009
8-other
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
PMID 19340529·Int J Hematol·2009
8-other
Treatment selection after imatinib resistance in chronic myeloid leukemia.
PMID 19343297·Target Oncol·2009
6-review
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
PMID 19117345·Cancer·2009
8-other
Reproductive medicine meets human embryonic stem cell (hESC) research: the need to adjust the regulatory framework to actual expectations and potential detrimental consequences of hESC research.
PMID 18692797·Fertil Steril·2009
8-other
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.
PMID 19013640·Leuk Res·2009
8-other
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
PMID 19029442·Blood·2009
3-trial
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia.
PMID 19118067·Clin Cancer Res·2009
8-other
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
PMID 19260121·Am J Hematol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2920 N 4TH ST
FLAGSTAFF, AZ 86004 - Phone
- (928) 522-9400
Quick Facts
- NPI
- 1225204381
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile